Pharmacoeconomic considerations in treating ovarian cancer

PharmacoEconomics

Volumn 17, Issue 2, 2000, Pages 133-150

  Bodurka Bevers, Diane ^a   Sun, Charlotte C ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; NAVELBINE; PACLITAXEL; TAMOXIFEN; THIOTEPA; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG COST; HEALTH ECONOMICS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW;

EID: 0034057951     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017020-00003     Document Type: Review

References (88)

1. American Cancer Society. Cancer facts & figures - 1998. Atlanta (GA): American Cancer Society, 1998
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606
3. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903
4. Whelan SL, Parkin DM, Masuyer E, editors, in collaboration with Smans M. Patterns of cancer in five continents. New York: Oxford University Press, 1990
5. American College of Obstetricians and Gynecologists (ACOG). Ovarian Cancer. ACOG Educ Bull 1998; 250: 1-10
6. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993; 2 Suppl. 71: 517-23
7. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984; 11: 209-26
8. Hartge P, Schiffman MH, Hoover R, et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161: 10-6
9. The WHO collaborative study of neoplasia and steroid contraceptives. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 1989: 18; 538-45
10. The cancer and steroid hormone study of the Centers for Disease Control and the National Institute of Child Health and Human Development: the reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987; 316: 650-5
11. Cramer DW, Hutchison GB, Welch WR, et al. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 1982; 307: 1047-51
12. Whittemore AS, Harris R, Itnyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II: invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136 (10): 1184-203
13. Schneider AP, II. Risk for ovarian cancer [letter]. N Engl J Med 1987; 317: 508-9
14. Rosenblatt KA, Szklo M, Rosenshein NB. Mineral fiber exposure and the development of ovarian cancer. Gynecol Oncol 1992; 45: 20-5
15. Parazzini F, Negri E, La Vecchia C, et al. The epidemiology of ovarian cancer. Gynecol Oncol 1991; 43: 9-23
16. Whittemore AS, Wu ML, Paffenbarger RS, et al. Epithelial ovarian cancer and the ability to conceive. Can Res 1989; 49: 4047-52
17. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331: 771-6
18. Whittemore AS. The risk of ovarian cancer after treatment for infertility. N Engl J Med 1994; 331: 805-6
19. Cramer DW, Welch WR, Scully RE, et al. Ovarian cancer and talc: a case-control study. Cancer 1982; 50: 372-6
20. Cramer DW. Lactase persistence and milk consumption as determinants of ovarian cancer. Am J Epidemiol 1989; 130: 904-10
21. Cramer DW, Harlow BL, Willet WC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989; 11: 66-71
22. Lynch HT, Lunch JF, Conway TA. Hereditary ovarian cancer. In: Rubin SC, Sutton GP, editors. Ovarian cancer. New York (NY): McGraw-Hill, 1993: 189-217
23. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336 (20): 1401-8
24. Khoo SK, Battistuttu D, Hurst T, et al. The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer. Cancer 1993; 72: 531-7
25. Hoskins PJ, O'Reilly SE, Swenerton KD, et al. Ten year outcomes of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992; 10: 1561-8
26. Omura GA, Brady MF, Homesley HD, et al. Long term follow up and prognostic factor analysis in advanced ovarian cancer: the Gynecol Oncol Group experience. J Clin Oncol 1991; 9: 1138-50
27. Van Houwelingen JC, ten Bokkel Huinink WW, Van der Burg MEL, et al. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989; 7: 769-73
28. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment and follow-up. JAMA 1995; 273: 491-7
29. Gershenson DM, Tortolero-Luna G, Malpica A, et al. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gynecol Clin North Am 1996; 23 (2): 475-543
30. Hoskins W, Rice L, Rubin S. Ovarian cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines: ovarian cancer. Oncology 1997; 11 (6): 896-900, 903-4
31. Olt GJ, Berchuck A, Bast Jr RC. Gynecologic tumor markers. Semin Surg Oncol 1990; 6: 305-13
32. Rustin GJS, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996, 14: 1545-51
33. Rustin GJS, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann Oncol 1996; 7: 361-4
34. Makar APH, Kristensen GB, Bormer OP, et al. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993; 49: 73-9
35. Staging announcement: FIGO Cancer Committee. Gynecol Oncol 1986; 25: 383-5
36. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25 (3): 326-34
37. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7
38. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6
39. Nicklin JL, Copeland LJ, Luesley DM, et al. Second-look surgery. In: Gershenson DM, McGuire WP, editor. Ovarian cancer: controversies in management. New York (NY): Churchill Livingstone Inc., 1998: 85-100
40. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93
41. Hoskins PJ, O'Reilly SE, Swenerton KD. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer 1991; 1: 205-8
42. Seltzer V, Vogl S, Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 1985; 21: 167-76
43. Carmichael J, Gordon A, Malfetano J, et al. Topotecan, a new active drug, vs paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group trial [abstract]. Proc Am Soc Clin Oncol 1996; 15: 283
44. Stiff P, Bayer R, Carmarda M, et al. A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autolugous bone marrow rescue for recurrent epithlelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 1995; 57: 278-85
45. Petereit DG, Sharda NN, Hollister TC, et al. Adjuvant whole abdominal radiation for low risk and intermediate risk (Dembo classification) ovarian cancer [abstract no. 191]. Gynecol Oncol 1997; 64: 339
46. Goldberg N, Peschel RE. Postoperative abdominopelvic radiation therapy for ovarian cancer. Int J Radial Oncol Biol Phys 1988; 14: 425-9
47. Weiser EB, Burke TW, Heller PB, et al. Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR). Gynecol Oncol 1988; 30: 201-8
48. Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer: a 10-year experience. Cancer 1985; 55: 2285-90
49. Dembo AJ, Bush RS, Beale FA, et al. The Princess Margaret Hospital study of ovarian cancer: stage I, II, and asymptomatic III presentations. Cancer Treat Rep 1979; 63: 249-54
50. May LF, Bellinson JL, Roland TA. Palliative benefit of radiation therapy in advanced ovarian cancer. Gynecol Oncol 1990; 37: 408-11
51. NCI-ASCO Economics Working Group. Integrating economic analysis into cancer clinical trials: the National Cancer Institute - American Society of Clinical Oncology Economics Workbook. J Natl Cancer Inst Monog 1998; 24: 1-28
52. Markman M. Management of CA-125 elevation in a patient with ovarian cancer but without other clinical evidence of disease. 33rd Annual Americal Society of Clinical Oncology Education Book Meeting; 1997 May 17-20; Denver (CO), 102-4
53. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Oncol 1996; 49 (1): 95-103
54. Bailes JS. Cost aspects of palliative cancer care. Semin Oncol 1995; 22 (2 Suppl. 3): 64-6
55. Doyle DC, Stockler M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997; 15 (3): 1000-7
56. Drug topics redbook. Montvale (NJ): Medical Economics Company, 1998
57. McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15 (2): 640-5
58. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15 (2): 632-9
59. Messori A, Trippoli S, Becagli P, et al. Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian carcinoma: a lifetime cost-effectiveness analysis. Cancer 1996; 78: 2366-73
60. Oncology Therapeutics Program. Oncology drug and supply sourcebook: for the community-based oncology practice. San Francisco (CA): Oncology Therapeutics Network, 1996
61. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant 1995; 15: 605-10
62. Glaspy JA, Jakway J. Cost considerations in therapy with myeloid growth factors. Am J Hosp Pharm 1993; 50 Suppl. 3: S19-27
63. Messori A, Trippoli S. Pharmacoeconomic profile of taxanes in advanced ovarian cancer. Anti-Cancer Drugs 1998; 9: 909-16
64. Drummond MF, O'Brien B, Stoddart CL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997
65. Drummond MF, Davies L. Economic analysis alongside clinical trials. Int J Technol Assess Health Care 1991; 7 (4): 561-73
66. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 1st ed. Ottawa (ON): CCOHTA, 1994
67. Cvitkovic E, Misset JL. Chemotherapy for ovarian cancer [letter]. N Engl J Med 1996; 334: 1269
68. Lacave JA, Pelaez I, Palacio I. Chemotherapy for ovarian cancer [letter]. N Engl J Med 1996; 334: 1269-70
69. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Support Care Cancer 1997; 5 (6): 489-99
70. Simes RJ. Application of statistical decision theory to treatment choices: implications for the design and analysis of clinical trials. Stat Med 1986; 5: 411-20
71. Ortega A, Dranitsaris G, Sturgeon J, et al. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997; 66 (3): 454-63
72. Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology 1995; 9 (11 Suppl.): 47-60
73. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300: 1458-60
74. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chron Dis 1978; 31: 697-704
75. Elit LM, Levine MN, Gafni A, et al. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol 1996; 62 (3): 329-35
76. Montazeri A, McEwen J, Gillis CR. Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer 1996; 4 (3): 169-79
77. Cain JM, Wenzel LB, Monk BJ, et al. Palliative care and quality of life considerations in the management of ovarian cancer. In: Gershenson DM, McGuire WP, editors. Ovarian cancer: controversies in management. New York (NY): Churchill Livingstone Inc., 1998: 281-307
78. Ozols RF. Outcome issues in ovarian cancer. Oncology 1995; 9 (11 Suppl.): 135-9
79. McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19: 357-68
80. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992; 35: 1505-9
81. Waiczak JR, Brady M. Comparison of quality of life in ovarian cancer patients participating in a national cooperative group phase III randomized trial [abstract]. Proc Am Soc Clin Oncol 1990; 10: A1185
82. Willemse PH, van Lith J, Mulder NH, et al. Risks and benefits of cisplatin in ovarian cancer: a quality-adjusted survival analysis. Eur J Cancer 1990; 26: 345-52
83. Small EC, Anderson B, Watring WG, et al. Ovarian carcinoma: management of stress in patients and physicians. Gynecol Oncol 1983; 15 (2): 160-5
84. Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993; 50: 202-7
85. Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59 (2): 231-42
86. Portenoy FK, Kornblith AB, Wong G, et al. Pain in ovarian cancer patients: prevalence, characteristics, and associated symptoms. Cancer 1994; 74: 907-15
87. Steginga SK, Dunn J. Women's experiences following treatment for gynecologic cancer. Oncol Nurs Forum 1997; 24 (8): 1403-8
88. Bodurka-Bevers D, Basen-Engquist KM, Fitzgerald MA, et al. Depression may worsen quality of life in patients with epithelial ovarian cancer [abstract]. Gynecol Oncol 1999; 72: 449